Word: oncologists
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...patients in the U.S. each year. In the drug's very first test, every patient went into remission. In the most recent results, 30% showed no sign of the chromosomal damage that marks the disease and appeared to have been cured. "This drug is amazing," says Richard Stone, an oncologist at the Dana-Farber Cancer Institute who has been testing Glivec (also known as an STI, for signal transduction inhibitor). "Even patients who are near death, at the end stage of this disease, are going into remission...
...fantastic voyage that scientists have taken into the heart of the cancer cell. "The life and death of cells is being worked out, and the dozens and dozens of molecules in the body that participate in those pathways are now becoming targets for therapy," says Alan Houghton, a medical oncologist and immunologist at Memorial Sloan-Kettering Cancer Center in New York City...
...fantastic voyage that scientists are taking into the heart of the cancer cell. "The life and death of cells is being worked out, and the dozens and dozens of molecules in the body that participate in those pathways are now becoming targets for therapy," says Alan Houghton, a medical oncologist and immunologist at Memorial Sloan-Kettering Cancer Center, in Manhattan...
...patients in the US each year. In the drug’s very first test, every patient went into remission. In the most recent results, 30 percent showed no chromosomal sign of disease and appeared to have been cured. "This drug is amazing," says Richard Stone, an oncologist at Dana-Farber Cancer Institute, in Boston, who has been testing Glivec (also known as an STI, for signal transduction inhibitor). "Even patients who are near death, at the end stage of this disease, are going into remission...
...treatments will fail clinical trials. But doctors who treat the disease are experiencing a surge of optimism the likes of which they have never seen. "It’s no longer spin the wheel, let’s try this drug, maybe it will work," says Henry Friedman, a neuro-oncologist at Duke University Medical Center. "We’re going to know why a drug is or isn’t working." And given the nature of cancer and the scientists who study it, if one approach doesn’t fly, there’ll be no shortage of crazy ideas to replace...